

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Richard L. Apodaca et al.

Serial No.: 10/692,080

Art Unit:

Filed

: October 23, 2003

Examiner:

For

· : PHENYLPIPERIDINES AND PHENYLPYRROLIDINES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.D. Box/1450, Alexandria, VA 22313-1450 on

(pate of Deposit)

John W. Harbour

(Name of applicant, assignee or Registered Representative)

(Signature)

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

#### FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on January 27, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

X In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [ ] the first or ☐second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

js ·	
	<pre>Statement in Accordance with §1.97(e)     (attached); or  Please charge Deposit Account No. 10-</pre>
	in §1.17(p).  In accordance with §1.97(d), this Information  Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee.  Applicant(s) hereby petition(s) for consideration of this
	Information Disclosure Statement. Included are: Statement in Accordance with $\$1.97(e)$ as set forth below and the fee of $\$180.00$ as set forth in $\$1.17(p)$ .
	☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.  ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
·	
	available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
·	Copies of only foreign patent documents and non- patent literature are enclosed in accordance with 37 CFR 1.98  (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed January 27, 2004.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-25/JWH. This form is submitted in triplicate.

Respectfully submitted,

Reg. No. 31,365

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2169

DATED: 4/30/04



# SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/692,080
Filing Date	October 23, 2003
First Named Inventor	Richard L. Apodaca et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD-25

### U.S. PATENT DOCUMENTS

<del></del>	<del> </del>		TENT DOCUMENTS			
			U.S. Patent Docum	nent	l <u></u>	
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Number	Kind Code <sup>2</sup> (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear	
	140.	<del></del>		<del></del>	• • • • • • • • • • • • • • • • • • • •	
	<b> </b>					
	1					
	-			,		
	i _l					
					,	
	1					
	<del>                                     </del>					
	İ				-	
					L	

### FOREIGN PATENT DOCUMENTS

		, only	TENI				<del>,</del>
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign Pa	Number <sup>4</sup>	KindCode <sup>5</sup>	Pages, Columns, Lines, where relevant passages or relevant figures appear	₹°
	<b>-</b>			<del>                                     </del>		<u> </u>	
					_		
				<del> </del>			
				<u> </u>			
				İ			
	·	OTHER PRIOR ART - N	ON PATENT	LITERATU	RE DOCUME	NTS	
Examiner 's Initials*	Cite No.1	Include name of the author (in Countitle of the item (book, magazine volume-issue number(s	, joumal, se	erial, symp	osium, catalo	og, etc.), date, page(s),	T²
		PCT International Search Report, dated	March 29, 2	2004, for PC	T Int'l. Appln. N	lo. PCT/US03/33809	
						·	
		-					
<del></del>	-						-
•							
			·				

Examiner	 _	 Date	$\neg$		
Signature		Consider	red		

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

Application Number	10/692,080
Filing Date	October 23, 2003
First Named Inventor	Richard L. Apodaca et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD-25

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code Examiner Cite of Cited Document where relevant passages of Cited Document Initials or relevant figures appear Number (if known) mm-dd-yyyy No.1

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Foreign	Patent Documer	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office <sup>3</sup> Number <sup>4</sup> KindCode <sup>5</sup>			Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>6</sup>
		EP	0 952 154	A2	Pfizer Products, Inc.	10-27-1999		
		EP	1 074 543	A1	Meiji Seika Kaisha, Ltd.	02-07-2001		
		wo	03/047520	A2	Bristol-Myers Squibb Company	06-12-2003		
		wo	03/053912	A1	Bristol -Myers Squibb Company	07-03-2003		

Examiner	Data	
Examiner	Date	ŀ
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450